Defunct Company
Total Trials
3
As Lead Sponsor
0
As Collaborator
Total Enrollment
125
NCT01497184
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood
Phase: Phase 1
Role: Collaborator
Start: Dec 31, 2011
Completion: Mar 8, 2021
NCT02529813
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Start: Dec 16, 2015
Completion: Nov 8, 2021
NCT03579888
CD19-Specific T Cells Post AlloSCT
Start: Jun 26, 2020
Completion: May 27, 2021